Sabine D. Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, shared a post by UroToday.com, on X:
“Excellent exchange and discussion
need for control arms in clinical trials reflecting SOC NMIBC need for accurate risk categorization of patients role of Biomarkers – ctDNA.
Quoting UroToday.com’s post:
“Guidelines aim to harmonize and optimize urothelial carcinoma clinical trials.
Ashish M. Kamat and Mathew Galsky join Sam S. Chang to discuss new trial parameters and the urgent need for detailed guidelines due to the dynamic landscape of treatment .
Authors: Ashish M. Kamat, Mathew Galsky, Sam S. Chang”
